⌘K
Loading ticker…
As of 2026-08-24, Immunome, Inc. (IMNM) has a 3-month relative strength percentile of 87 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 70. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 5.7%, relative volume 1.61×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
IMNM is in a stage 2 uptrend, week 1. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: 20.4% / 28.4%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
IMNM is held by 21 ETFs as of May 2026. Top owner: VTWO at 0.07% weight, $11M notional. Top 3 carry $29M.
Held by 52 ETFs · $295M across latest filings · largest weight 3.91% (CANC).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.07% | $11M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.05% | $11M | — |
| CANC | 3.91% | $7M | +1.24 pp |
| VHTVanguard Health Care ETF | 0.03% | $6M | — |
| VFMO | 0.15% | $3M | +0.04 pp |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.12% |
| $2M |
| — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $1M | — |
| ESML | 0.05% | $1M | — |
| ONEQ | 0.01% | $674K | — |
| GSSC | 0.04% | $401K | new |
Showing 10 of 21 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | IMNM Jan avg: 53.18% median: 34.74% win: 100% σ: 61.51% n: 4 2022-04-12 → 2026-07-31 | IMNM Feb avg: 1.61% median: -12.41% win: 25% σ: 29.66% n: 4 2022-04-12 → 2026-07-31 | IMNM Mar avg: -4.30% median: 1.01% win: 75% σ: 16.55% n: 4 2022-04-12 → 2026-07-31 | IMNM Apr avg: -6.74% median: -4.01% win: 40% σ: 27.80% n: 5 2022-04-12 → 2026-07-31 | IMNM May avg: 2.79% median: 3.46% win: 60% σ: 5.57% n: 5 2022-04-12 → 2026-07-31 | IMNM Jun avg: 3.54% median: -2.93% win: 40% σ: 28.49% n: 5 2022-04-12 → 2026-07-31 | IMNM Jul avg: 11.89% median: 13.12% win: 80% σ: 14.15% n: 5 2022-04-12 → 2026-07-31 | IMNM Aug avg: 6.69% median: -5.55% win: 25% σ: 27.65% n: 4 2022-04-12 → 2026-07-31 (current) | IMNM Sep avg: 6.56% median: 9.72% win: 50% σ: 24.20% n: 4 2022-04-12 → 2026-07-31 | IMNM Oct avg: 4.82% median: 1.79% win: 50% σ: 24.43% n: 4 2022-04-12 → 2026-07-31 | IMNM Nov avg: 4.18% median: 6.91% win: 50% σ: 15.33% n: 4 2022-04-12 → 2026-07-31 | IMNM Dec avg: -2.62% median: -2.51% win: 50% σ: 40.80% n: 4 2022-04-12 → 2026-07-31 |